Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | UBE2N | P61088 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365349 | 1.00 | HSP90AB1 (0.41) | HSP90AB1AKR1C2AKR1C1AKR1C4AKR1C3 | |
| SCHEMBL27992218 | 0.84 | CES2 (0.38) | HSP90AB1AKR1C2AKR1C1AKR1C4AKR1C3 | |
| SCHEMBL31425832 | 0.84 | AKR1C2 (0.40) | AKR1C2AKR1C1AKR1C4AKR1C3MAPT | |
| SCHEMBL11708450 | 0.81 | AKR1C4 (0.60) | HSP90AB1AKR1C2AKR1C1AKR1C4AKR1C3 | |
| SCHEMBL20392559 | 0.81 | DGAT1 (0.40) | HSP90AB1HMGCRMAPTKDM4EDGAT1 | |
| SCHEMBL10712789 | 0.80 | AKR1C3 (0.58) | HSP90AB1AKR1C2AKR1C1AKR1C4AKR1C3 | |
| SCHEMBL17210813 | 0.80 | KDM4E (0.44) | HSP90AB1AKR1C2AKR1C1AKR1C4AKR1C3 | |
| SCHEMBL1019833 | 0.79 | AKR1C2 (0.42) | AKR1C2AKR1C1AKR1C4AKR1C3MAPT | |
| SCHEMBL26264218 | 0.79 | MAPT (0.36) | HSP90AB1HMGCRMAPTHSD17B10DGAT1 | |
| SCHEMBL27833587 | 0.79 | HSP90AB1 (0.41) | HSP90AB1AKR1C2AKR1C1AKR1C4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415771-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2025-09-16 | — | — | US | disclosed |
| EP-3986852-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2024-10-16 | — | — | EP | disclosed |
| US-20220388938-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2022-12-08 | — | — | US | disclosed |
| EP-3986852-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| CN-114008012-A | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020254559-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254559-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
| CN-102036976-B | Modulators of dopamine neurotransmission | NSAB AF NEUROSEARCH SWEDEN AB | 2013-05-01 | — | — | CN | disclosed |
| CN-102036976-A | Modulators of dopamine neurotransmission | NSAB AF NEUROSEARCH SWEDEN AB | 2011-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388938-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | RYR1, CACNB1, SMN1; SMN2 | HSP90AB1 1596/4885AKR1C2 3742/4885AKR1C1 3594/4885 |
| US-12415771-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, SMN1; SMN2 | HSP90AB1 1596/4885AKR1C2 3742/4885AKR1C1 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.